Aeterna Zentaris Announces Transfer of Manufacturing Rights Related to Cetrotide® to Merck KGaA

Aeterna Zentaris Announces Transfer of Manufacturing Rights Related to 
Cetrotide® to Merck KGaA 
All amounts are in US dollars (unless otherwise mentioned) 
QUÉBEC CITY, April 17, 2013 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ: 
AEZS) (TSX: AEZ) (the"Company") today announced that its German subsidiary 
has entered into binding agreements with various partners and licensees with 
respect to the manufacturing rights and obligations for its Cetrotide(®) 
product. The principal effect of such agreements is to transfer manufacturing 
rights and to grant a manufacturing license for Cetrotide(®) to a subsidiary 
of Merck KGaA of Darmstadt, Germany ("Merck Serono"), in all jurisdictions. 
Subject to the satisfaction of customary closing conditions, the transaction 
is expected to be completed on or about October 1, 2013, at which time Aeterna 
Zentaris would receive a one-time payment of €2.5 million, or approximately 
$3.2 million and certain other payments. In addition, the Company has also 
entered into a transitional services agreement with Merck KGaA under which the 
Company will, during a 36-month period, provide various transition services to 
assist Merck KGaA in assuming responsibility for the manufacturing of 
Cetrotide(®) in consideration for the payment of a monthly fee to the Company 
throughout such period. 
Cetrotide(®) (cetrorelix acetate for injection) is used to regulate hormone 
responses in women undergoing infertility treatment. Merck Serono, a leader in 
the field of fertility treatments, currently markets Cetrotide(®) worldwide, 
excluding Japan. 
The Company had previously monetized the royalty stream related to 
Cetrotide(®) in November 2008 in a transaction with HealthCare Royalty 
Partners L.P. (formerly Cowen Healthcare Royalty Partners L.P.). With the 
transfer of manufacturing rights to Merck Serono, Aeterna Zentaris remains 
focused on its Phase 3 trial in endometrial cancer and Phase 2 trials in 
breast, prostate and bladder cancer with AEZS-108, its upcoming NDA filing for 
AEZS-130 as an oral diagnostic test for growth hormone deficiency in adults, 
as well as its earlier-stage oncology compounds, including AEZS-120. 
The use of the name "Merck" and "Merck Serono" in this press release refers to 
Merck KGaA of Darmstadt, Germany. In North America, Merck KGaA operates under 
the umbrella brand EMD. 
About Aeterna Zentaris 
Aeterna Zentaris is an oncology and endocrinology drug development company 
currently investigating treatments for various unmet medical needs. The 
Company's pipeline encompasses compounds at all stages of development, from 
drug discovery through to marketed products. For more information please visit 
Forward-Looking Statements 
This press release contains forward-looking statements made pursuant to the 
safe harbour provisions of the U.S. Securities Litigation Reform Act of 1995. 
Forward-looking statements involve known and unknown risks and uncertainties 
that could cause the Company's actual results to differ materially from those 
in the forward-looking statements. Such risks and uncertainties include, among 
others, the availability of funds and resources to pursue R&D projects, the 
successful and timely completion of clinical studies, the risk that safety and 
efficacy data from any of our Phase 3 trials may not coincide with the data 
analyses from previously reported Phase 1 and/or Phase 2 clinical trials, the 
ability of the Company to take advantage of business opportunities in the 
pharmaceutical industry, uncertainties related to the regulatory process and 
general changes in economic conditions. Investors should consult the Company's 
quarterly and annual filings with the Canadian and U.S. securities commissions 
for additional information on risks and uncertainties relating to 
forward-looking statements. Investors are cautioned not to rely on these 
forward-looking statements. The Company does not undertake to update these 
forward-looking statements. We disclaim any obligation to update any such 
factors or to publicly announce the result of any revisions to any of the 
forward-looking statements contained herein to reflect future results, events 
or developments, unless required to do so by a governmental authority or by 
applicable law. 
Investor Relations Ginette Beaudet Vallières Investor Relations Coordinator 
(418) 652-8525 ext. 265 
Media Relations Paul Burroughs Director of Communications (418) 652-8525 ext. 
To view this news release in HTML formatting, please use the following URL: 
ST: Quebec
-0- Apr/17/2013 11:30 GMT
Press spacebar to pause and continue. Press esc to stop.